Search

Your search keyword '"Holkova, Beata"' showing total 47 results
Start Over Author "Holkova, Beata" Publication Year Range Last 10 years
47 results on '"Holkova, Beata"'

1. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

Author

Yazbeck, Victor, Shafer, Danielle, Perkins, Edward B., Coppola, Domenico, Sokol, Lubomir, Richards, Kristy L., Shea, Thomas, Ruan, Jia, Parekh, Samir, Strair, Roger, Flowers, Christopher, Morgan, David, Kmieciak, Maciej, Bose, Prithviraj, Kimball, Amy, Badros, Ashraf Z., Baz, Rachid, Lin, Hui-Yi, Zhao, Xiuhua, Reich, Richard R., Tombes, Mary Beth, Shrader, Ellen, Sankala, Heidi, Roberts, John D., Sullivan, Daniel, Grant, Steven, and Holkova, Beata

Published
2018
Full Text
View/download PDF

3. Supplementary Table 2 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Author

Holkova, Beata, primary, Supko, Jeffrey G., primary, Ames, Matthew M., primary, Reid, Joel M., primary, Shapiro, Geoffrey I., primary, Perkins, Edward Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Honeycutt, Connie, primary, McGovern, Renee M., primary, Kmieciak, Maciej, primary, Shrader, Ellen, primary, Wellons, Martha D., primary, Sankala, Heidi, primary, Doyle, Austin, primary, Wright, John, primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Table 3 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Author

Holkova, Beata, primary, Supko, Jeffrey G., primary, Ames, Matthew M., primary, Reid, Joel M., primary, Shapiro, Geoffrey I., primary, Perkins, Edward Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Honeycutt, Connie, primary, McGovern, Renee M., primary, Kmieciak, Maciej, primary, Shrader, Ellen, primary, Wellons, Martha D., primary, Sankala, Heidi, primary, Doyle, Austin, primary, Wright, John, primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table 1 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Author

Holkova, Beata, primary, Supko, Jeffrey G., primary, Ames, Matthew M., primary, Reid, Joel M., primary, Shapiro, Geoffrey I., primary, Perkins, Edward Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Honeycutt, Connie, primary, McGovern, Renee M., primary, Kmieciak, Maciej, primary, Shrader, Ellen, primary, Wellons, Martha D., primary, Sankala, Heidi, primary, Doyle, Austin, primary, Wright, John, primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Methods from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Author

Holkova, Beata, primary, Supko, Jeffrey G., primary, Ames, Matthew M., primary, Reid, Joel M., primary, Shapiro, Geoffrey I., primary, Perkins, Edward Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Honeycutt, Connie, primary, McGovern, Renee M., primary, Kmieciak, Maciej, primary, Shrader, Ellen, primary, Wellons, Martha D., primary, Sankala, Heidi, primary, Doyle, Austin, primary, Wright, John, primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Materials from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Author

Holkova, Beata, primary, Kmieciak, Maciej, primary, Perkins, E. Brent, primary, Bose, Prithviraj, primary, Baz, Rachid C., primary, Roodman, G. David, primary, Stuart, Robert K., primary, Ramakrishnan, Viswanathan, primary, Wan, Wen, primary, Peer, Cody J., primary, Dawson, Jana, primary, Kang, Loveleen, primary, Honeycutt, Connie, primary, Tombes, Mary Beth, primary, Shrader, Ellen, primary, Weir-Wiggins, Caryn, primary, Wellons, Martha, primary, Sankala, Heidi, primary, Hogan, Kevin T., primary, Colevas, A. Dimitrios, primary, Doyle, L. Austin, primary, Figg, William D., primary, Coppola, Domenico, primary, Roberts, John D., primary, Sullivan, Daniel, primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Data from Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

Author

Holkova, Beata, primary, Perkins, E. Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Shrader, Ellen, primary, Talreja, Neha, primary, Wellons, Martha D., primary, Hogan, Kevin T., primary, Roodman, G. David, primary, Coppola, Domenico, primary, Kang, Loveleen, primary, Dawson, Jana, primary, Stuart, Robert K., primary, Peer, Cody, primary, Figg, William D., primary, Kolla, Sarah, primary, Doyle, Austin, primary, Wright, John, primary, Sullivan, Daniel M., primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

11. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.

Author

Lonial, Sagar, primary, Grosicki, Sebastian, additional, Hus, Marek, additional, Song, Kevin W., additional, Facon, Thierry, additional, Callander, Natalie Scott, additional, Ribrag, Vincent, additional, Uttervall, Katarina, additional, Quach, Hang, additional, Vorobyev, Vladimir I., additional, Min, Chang Ki, additional, Cheng, Shinta, additional, Smith, L. Mary, additional, Yu, Jing, additional, Collingwood, Therese, additional, Holkova, Beata, additional, Kremer, Brandon, additional, Gupta, Ira, additional, Richardson, Paul G., additional, and Minnema, Monique C., additional

Published
2022
Full Text
View/download PDF

12. DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Author

Callander, Natalie S., primary, Ribrag, Vincent, additional, Richardson, Paul G., additional, Nooka, Ajay K., additional, Song, Kevin, additional, Uttervall, Katarina, additional, Minnema, Monique C., additional, Weisel, Katja, additional, Quach, Hang, additional, Min, Chang-Ki, additional, Ballas, Marc S., additional, Li, Xiaofang, additional, Ratia, Nirav, additional, Kaisermann, Morrys, additional, Holkova, Beata, additional, and Trudel, Suzanne, additional

Published
2021
Full Text
View/download PDF

13. P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)

Author

Richardson, Paul G., primary, Trudel, Suzanne, additional, Callander, Natalie S., additional, Nooka, Ajay, additional, Song, Kevin, additional, Uttervall, Katarina, additional, Minnema, Monique C., additional, Rodríguez-Otero, Paula, additional, Struemper, Herbert, additional, Yeakey, Anne, additional, de Oca, Rocio Montes, additional, Smith, L. Mary, additional, Jackson, Nicola, additional, Kaisermann, Morrys, additional, Im, Ellie, additional, Basile, Frank G., additional, Ahlers, Christoph M., additional, Holkova, Beata, additional, Gupta, Ira, additional, Kremer, Brandon E., additional, and Quach, Hang, additional

Published
2021
Full Text
View/download PDF

16. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Author

Nooka, Ajay K, primary, Weisel, Katja, additional, van de Donk, Niels WCJ, additional, Routledge, David, additional, Otero, Paula Rodriguez, additional, Song, Kevin, additional, Quach, Hang, additional, Callander, Natalie, additional, Minnema, Monique C, additional, Trudel, Suzanne, additional, Jackson, Nicola A, additional, Ahlers, Christoph M, additional, Im, Ellie, additional, Cheng, Shinta, additional, Smith, L, additional, Hareth, Nahi, additional, Ferron-Brady, Geraldine, additional, Brouch, Maria, additional, Montes de Oca, Rocio, additional, Paul, Sofia, additional, Holkova, Beata, additional, Gupta, Ira, additional, Kremer, Brandon E, additional, and Richardson, Paul, additional

Published
2021
Full Text
View/download PDF

17. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Nooka, Ajay K, Weisel, Katja, van de Donk, Niels Wcj, Routledge, David, Otero, Paula Rodriguez, Song, Kevin, Quach, Hang, Callander, Natalie, Minnema, Monique C, Trudel, Suzanne, Jackson, Nicola A, Ahlers, Christoph M, Im, Ellie, Cheng, Shinta, Smith, L, Hareth, Nahi, Ferron-Brady, Geraldine, Brouch, Maria, de Oca, Rocio Montes, Paul, Sofia, Holkova, Beata, Gupta, Ira, Kremer, Brandon E, Richardson, Paul, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Nooka, Ajay K, Weisel, Katja, van de Donk, Niels Wcj, Routledge, David, Otero, Paula Rodriguez, Song, Kevin, Quach, Hang, Callander, Natalie, Minnema, Monique C, Trudel, Suzanne, Jackson, Nicola A, Ahlers, Christoph M, Im, Ellie, Cheng, Shinta, Smith, L, Hareth, Nahi, Ferron-Brady, Geraldine, Brouch, Maria, de Oca, Rocio Montes, Paul, Sofia, Holkova, Beata, Gupta, Ira, Kremer, Brandon E, and Richardson, Paul

Published
2021

18. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Author

Holkova, Beata, primary, Shafer, Danielle, additional, Yazbeck, Victor, additional, Dave, Sandeep, additional, Bose, Prithviraj, additional, Tombes, Mary Beth, additional, Shrader, Ellen, additional, Wan, Wen, additional, Bandyopadhyay, Dipankar, additional, Weir, Caryn, additional, Collins, Elizabeth B., additional, Garnett, Amanda, additional, Kmieciak, Maciej, additional, Roberts, John D., additional, Garcia-Manero, Guillermo, additional, and Grant, Steven, additional

Published
2020
Full Text
View/download PDF

19. Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Richardson, Paul G., primary, Nooka, Ajay, additional, Quach, Hang, additional, Trudel, Suzanne, additional, Routledge, David, additional, Song, Kevin, additional, Nahi, Hareth, additional, Paul, Sofia, additional, Khan, Josephine, additional, Brouch, Maria, additional, Ferron-Brady, Geraldine, additional, Yeakey, Anne, additional, Shelton, Chris, additional, Montes de Oca, Rocio, additional, Smith, L. Mary, additional, Im, Ellie, additional, Ahlers, Christoph M, additional, Paul, Elaine M, additional, Holkova, Beata, additional, Gupta, Ira, additional, Kremer, Brandon E., additional, and Rodriguez-Otero, Paula, additional

Published
2020
Full Text
View/download PDF

20. DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

Author

Richardson, Paul G., primary, Biswas, Swethajit, additional, Holkova, Beata, additional, Jackson, Nicola, additional, Netherway, Thelma, additional, Paul, Sofia, additional, Ferron-Brady, Geraldine, additional, Yeakey, Anne, additional, Shelton, Chris, additional, Montes de Oca, Rocio, additional, Ahlers, Christoph Matthias, additional, Ballas, Marc S., additional, Paul, Elaine Marie, additional, Gupta, Ira, additional, Opalinska, Joanna, additional, and Luptakova, Katarina, additional

Published
2020
Full Text
View/download PDF

22. Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Author

Richardson, Paul G., primary, Biswas, Swethajit, additional, Holkova, Beata, additional, Jackson, Nicola, additional, Netherway, Thelma, additional, Bao, Weichao, additional, Ferron-Brady, Geraldine, additional, Yeakey, Anne, additional, Shelton, Chris, additional, Montes De Oca, Rocio, additional, Ahlers, Chris, additional, Franco, Sonia, additional, Ballas, Marc, additional, Paul, Elaine, additional, Luptakova, Katarina, additional, Gupta, Ira, additional, and Opalinska, Joanna, additional

Published
2019
Full Text
View/download PDF

23. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.

Author

Holkova, Beata, Shafer, Danielle, Yazbeck, Victor, Dave, Sandeep, Bose, Prithviraj, Tombes, Mary Beth, Shrader, Ellen, Wan, Wen, Bandyopadhyay, Dipankar, Weir, Caryn, Collins, Elizabeth B., Garnett, Amanda, Kmieciak, Maciej, Roberts, John D., Garcia-Manero, Guillermo, and Grant, Steven

Subjects
*MYELODYSPLASTIC syndromes, *ACUTE leukemia, *BORTEZOMIB, *CHRONIC myeloid leukemia
Abstract

We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4, 8, and 11 every 21 days. QTc prolongation was the only identified DLT. The RP2Ds were 1.3 mg/m2 bortezomib and 1000 mg/m2 belinostat. One patient with highly refractory MLL-ENL rearranged biphenotypic AML with multiple karyotypic aberrations had a complete pathologic and karyotypic response. One patient with post-MPN AML remained on study with stable disease (SD) for 32 cycles. Whole-exome sequencing revealed no aberrations in the first patient and a hyper-mutator genotype in the second. Eighteen patients had a best response of SD. We conclude that this treatment strategy is feasible but has limited activity in this population. Nevertheless, the factors that predict exceptional responses to this strategy warrant further investigation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

Author

Friedberg, Jonathan W., primary, Forero-Torres, Andres, additional, Holkova, Beata, additional, Goldschmidt, Jerome H., additional, Boccia, Ralph V., additional, Bordoni, Rodolfo, additional, Cline, Vivian Jean M., additional, Patel-Donnelly, Dipti, additional, Flynn, Patrick J., additional, Olsen, Gregg A., additional, Chen, Robert W., additional, Galderisi, Faith, additional, Wang, Yinghui, additional, Sharman, Jeff Porter, additional, and Yasenchak, Christopher A., additional

Published
2018
Full Text
View/download PDF

26. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

Author

Chari, Ajai, primary, Larson, Sarah, additional, Holkova, Beata, additional, Cornell, Robert F., additional, Gasparetto, Cristina, additional, Karanes, Chatchada, additional, Matous, Jeffrey V., additional, Niesvizky, Ruben, additional, Valent, Jason, additional, Lunning, Matthew, additional, Usmani, Saad Z., additional, Anderson, Larry D., additional, Chang, Lipo, additional, Lee, Yihua, additional, Pak, Yvonne, additional, Salman, Zeena, additional, Graef, Thorsten, additional, Bilotti, Elizabeth, additional, and Chhabra, Saurabh, additional

Published
2018
Full Text
View/download PDF

28. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

Author

Holkova, Beata, primary, Yazbeck, Victor, additional, Kmieciak, Maciej, additional, Bose, Prithviraj, additional, Ma, Shuo, additional, Kimball, Amy, additional, Tombes, Mary Beth, additional, Shrader, Ellen, additional, Wan, Wen, additional, Weir-Wiggins, Caryn, additional, Singh, Amanda, additional, Hogan, Kevin T., additional, Conine, Sarah, additional, Sankala, Heidi, additional, Roberts, John D., additional, Shea, Thomas C., additional, and Grant, Steven, additional

Published
2017
Full Text
View/download PDF

30. Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Author

Budde, Lihua E., primary, Halwani, Ahmad, additional, Yasenchak, Christopher A., additional, Farber, Charles Michael, additional, Burke, John M, additional, Fayad, Luis E., additional, Holkova, Beata, additional, Knapp, Mark, additional, Kolibaba, Kathryn S., additional, Advani, Ranjana H, additional, Ansell, Stephen M, additional, Patel-Donnelly, Dipti, additional, Yimer, Habte A., additional, Smith, Scott E., additional, Levy, Moshe Yair, additional, Seetharam, Mahesh, additional, Belada, David, additional, Brooks, Donald, additional, Kingsley, Edwin C., additional, Klein, Leonard M., additional, Wagner-Johnston, Nina, additional, Ruffner, Katherine, additional, and Bartlett, Nancy L, additional

Published
2016
Full Text
View/download PDF

33. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Author

Holkova, Beata, primary, Zingone, Adriana, additional, Kmieciak, Maciej, additional, Bose, Prithviraj, additional, Badros, Ashraf Z., additional, Voorhees, Peter M., additional, Baz, Rachid, additional, Korde, Neha, additional, Lin, Hui-Yi, additional, Chen, Jin-Qiu, additional, Herrmann, Michelle, additional, Xi, Liqiang, additional, Raffeld, Mark, additional, Zhao, Xiuhua, additional, Wan, Wen, additional, Tombes, Mary Beth, additional, Shrader, Ellen, additional, Weir-Wiggins, Caryn, additional, Sankala, Heidi, additional, Hogan, Kevin T., additional, Doyle, Austin, additional, Annunziata, Christina M., additional, Wellons, Martha, additional, Roberts, John D., additional, Sullivan, Daniel, additional, Landgren, Ola, additional, and Grant, Steven, additional

Published
2016
Full Text
View/download PDF

34. Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Author

Chari, Ajai, primary, Chhabra, Saurabh, additional, Usmani, Saad, additional, Larson, Sarah, additional, Niesvizky, Ruben, additional, Matous, Jeffrey, additional, Gasparetto, Cristina, additional, Holkova, Beata, additional, Lunning, Matthew, additional, Valent, Jason, additional, Anderson, Larry D., additional, Karanes, Chatchada, additional, Kwei, Long, additional, Chang, Lipo, additional, Graef, Thorsten, additional, Bilotti, Elizabeth, additional, and McDonagh, Kevin, additional

Published
2015
Full Text
View/download PDF

35. Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Author

Yasenchak, Christopher A., primary, Halwani, Ahmad, additional, Advani, Ranjana, additional, Ansell, Stephen, additional, Budde, Lihua Elizabeth, additional, Burke, John M., additional, Farber, Charles M., additional, Holkova, Beata, additional, Fayad, Luis E., additional, Kolibaba, Kathryn S., additional, Knapp, Mark, additional, Li, Martha, additional, Manley, Thomas J., additional, Patel-Donnelly, Dipti, additional, Seetharam, Mahesh, additional, Yimer, Habte A., additional, and Bartlett, Nancy L, additional

Published
2015
Full Text
View/download PDF

36. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

Author

Holkova, Beata, primary, Kmieciak, Maciej, additional, Bose, Prithviraj, additional, Yazbeck, Victor Y., additional, Barr, Paul M., additional, Tombes, Mary Beth, additional, Shrader, Ellen, additional, Weir-Wiggins, Caryn, additional, Rollins, April D., additional, Cebula, Erin M., additional, Pierce, Emily, additional, Herr, Megan, additional, Sankala, Heidi, additional, Hogan, Kevin T., additional, Wan, Wen, additional, Feng, Changyong, additional, Peterson, Derick R., additional, Fisher, Richard I., additional, Grant, Steven, additional, and Friedberg, Jonathan W., additional

Published
2015
Full Text
View/download PDF

38. Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).

Author

Bartlett, Nancy L., primary, Farber, Charles M., additional, Yasenchak, Christopher A., additional, Ansell, Stephen Maxted, additional, Advani, Ranjana H., additional, Knapp, Mark H., additional, Fayad, Luis, additional, Kolibaba, Kathryn S., additional, Patel-Donnelly, Dipti, additional, Seetharam, Mahesh, additional, Yimer, Habte Aragaw, additional, Manley, Thomas John, additional, Burke, John M., additional, Holkova, Beata, additional, Budde, L. Elizabeth, additional, and Halwani, Ahmad Sami, additional

Published
2015
Full Text
View/download PDF

39. Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Author

Forero-Torres, Andres, primary, Holkova, Beata, additional, Sharman, Jeff P., additional, Friedberg, Jonathan W., additional, Berkowitz, Maurice J., additional, Fintel, William, additional, Chen, Robert, additional, Boccia, Ralph V., additional, Saleh, Mansoor, additional, Josephson, Neil, additional, Palanca-Wessels, Maria Corinna, additional, and Yasenchak, Christopher A., additional

Published
2014
Full Text
View/download PDF

40. Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Author

Holkova, Beata, primary, Kmieciak, Maciej, additional, Bose, Prithviraj, additional, Ma, Shuo, additional, Kimball, Amy, additional, Tombes, Mary Beth, additional, Shrader, Ellen, additional, Wan, Wen, additional, Weir-Wiggins, Caryn, additional, Stoddert, Elizabeth, additional, Singh, Amanda Garnett, additional, Dean, April, additional, Conine, Sarah, additional, Sankala, Heidi, additional, Roberts, John D., additional, Shea, Thomas C., additional, and Grant, Steven, additional

Published
2014
Full Text
View/download PDF

41. Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study

Author

Yasenchak, Christopher A., primary, Farber, Charles M., additional, Budde, Lihua Elizabeth, additional, Ansell, Stephen M., additional, Advani, Ranjana, additional, Holkova, Beata, additional, Halwani, Ahmad, additional, Knapp, Mark, additional, Fayad, Luis, additional, Kolibaba, Kathryn S., additional, Patel-Donnelly, Dipti, additional, Seetharam, Mahesh, additional, Manley, Thomas J., additional, and Bartlett, Nancy L., additional

Published
2014
Full Text
View/download PDF

42. Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Author

Holkova, Beata, primary, Kmieciak, Maciej, additional, Perkins, E. Brent, additional, Bose, Prithviraj, additional, Baz, Rachid C., additional, Roodman, G. David, additional, Stuart, Robert K., additional, Ramakrishnan, Viswanathan, additional, Wan, Wen, additional, Peer, Cody J., additional, Dawson, Jana, additional, Kang, Loveleen, additional, Honeycutt, Connie, additional, Tombes, Mary Beth, additional, Shrader, Ellen, additional, Weir-Wiggins, Caryn, additional, Wellons, Martha, additional, Sankala, Heidi, additional, Hogan, Kevin T., additional, Colevas, A. Dimitrios, additional, Doyle, L. Austin, additional, Figg, William D., additional, Coppola, Domenico, additional, Roberts, John D., additional, Sullivan, Daniel, additional, and Grant, Steven, additional

Published
2014
Full Text
View/download PDF

44. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.

Author

Holkova, Beata, Kmieciak, Maciej, Bose, Prithviraj, Yazbeck, Victor Y., Barr, Paul M., Tombes, Mary Beth, Shrader, Ellen, Weir-Wiggins, Caryn, Rollins, April D., Cebula, Erin M., Pierce, Emily, Herr, Megan, Sankala, Heidi, Hogan, Kevin T., Wan, Wen, Feng, Changyong, Peterson, Derick R., Fisher, Richard I., Grant, Steven, and Friedberg, Jonathan W.

Subjects
*CANCER relapse, *B cell lymphoma, *PNEUMONIA, *HYPONATREMIA, *FEBRILE neutropenia
Abstract

A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat was given orally twice daily on days 1, 2, 3, 8, 9, 10, 15, 16, and 17 followed by carfilzomib (given as a 30-min infusion) on days 1, 2, 8, 9, 15, and 16. A treatment cycle was 28 days. Dose escalation initially followed a standard 3 + 3 design, but adapted a more conservative accrual rule following dose de-escalation. The maximum tolerated dose was 20 mg/m² carfilzomib and 100 mg vorinostat (twice daily). The dose-limiting toxicities were grade 3 pneumonitis, hyponatremia, and febrile neutropenia. One patient had a partial response and two patients had stable disease. Correlative studies showed a decrease in NF-κB activation and an increase in Bim levels in some patients, but these changes did not correlate with clinical response. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

46. Bortezomibfor the treatment of non-Hodgkin’s lymphoma

Author

Bose, Prithviraj, Batalo, Michael S, Holkova, Beata, and Grant, Steven

Abstract

Introduction:Bortezomib, the first proteasome inhibitor (PI) to be evaluated in humans, is approved in the USA and Europe for the treatment of patients with multiple myeloma, and in the USA for patients with relapsed mantle cell lymphoma (MCL).Areas covered:This review examines the role of bortezomib in the therapy of non-Hodgkin’s lymphoma (NHL). Bortezomib may be particularly effective against the NF-κB-dependent activated B-cell subtype of diffuse large B-cell lymphoma. The combination of bortezomib with rituximab and dexamethasone represents a standard approach for the treatment of Waldenström’s macroglobulinemia, and that with bendamustine and rituximab has demonstrated excellent efficacy in follicular lymphoma. Combinations with other novel agents, such as inhibitors of cyclin-dependent kinases or histone deacetylases, also hold substantial promise in NHL. Unmet needs in NHL, competitor compounds, chemistry, pharmacokinetics, pharmacodynamics and safety and tolerability of bortezomib are also discussed.Expert opinion:The success of bortezomib in MCL has validated the proteasome as a therapeutic target in NHL. Rational combinations, for example, with Bruton’s tyrosine kinase inhibitors or BH3-mimetics, may hold the key to optimizing the therapeutic potential of PIs in NHL. Future trials are likely to involve newer agents with improved pharmacodynamic (e.g., carfilzomib, marizomib) or pharmacokinetic (e.g., ixazomib, oprozomib) properties.

Published
2014
Full Text
View/download PDF

47. Bortezomib for the treatment of non-Hodgkin's lymphoma.

Author

Bose P, Batalo MS, Holkova B, and Grant S

Subjects
Antineoplastic Agents pharmacokinetics, Antineoplastic Agents pharmacology, Boronic Acids pharmacokinetics, Boronic Acids pharmacology, Bortezomib, Humans, Multiple Myeloma drug therapy, Proteasome Inhibitors pharmacokinetics, Proteasome Inhibitors pharmacology, Pyrazines pharmacokinetics, Pyrazines pharmacology, Antineoplastic Agents therapeutic use, Boronic Acids therapeutic use, Lymphoma, Non-Hodgkin drug therapy, Proteasome Inhibitors therapeutic use, Pyrazines therapeutic use
Abstract

Introduction: Bortezomib , the first proteasome inhibitor (PI) to be evaluated in humans, is approved in the USA and Europe for the treatment of patients with multiple myeloma, and in the USA for patients with relapsed mantle cell lymphoma (MCL)., Areas Covered: This review examines the role of bortezomib in the therapy of non-Hodgkin's lymphoma (NHL). Bortezomib may be particularly effective against the NF-κB-dependent activated B-cell subtype of diffuse large B-cell lymphoma. The combination of bortezomib with rituximab and dexamethasone represents a standard approach for the treatment of Waldenström's macroglobulinemia, and that with bendamustine and rituximab has demonstrated excellent efficacy in follicular lymphoma. Combinations with other novel agents, such as inhibitors of cyclin-dependent kinases or histone deacetylases, also hold substantial promise in NHL. Unmet needs in NHL, competitor compounds, chemistry, pharmacokinetics, pharmacodynamics and safety and tolerability of bortezomib are also discussed., Expert Opinion: The success of bortezomib in MCL has validated the proteasome as a therapeutic target in NHL. Rational combinations, for example, with Bruton's tyrosine kinase inhibitors or BH3-mimetics, may hold the key to optimizing the therapeutic potential of PIs in NHL. Future trials are likely to involve newer agents with improved pharmacodynamic (e.g., carfilzomib, marizomib) or pharmacokinetic (e.g., ixazomib, oprozomib) properties.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results